Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriCombo study of TBI-1301 + CHP:NE1 for refractory soft tissue sarcoma
jRCT2090220346Phase 2Completed
- Sponsor
- Mikiya Ishihara
- Start
- May 2018
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-NY-ESO-1 TCR-T and UI-201 in soft tissue sarcoma (STS), sponsored by Mikiya Ishihara. Primary endpoints: Safety (Phase 1) and Tumor response (Phase 2). Started May 2018; status: completed.
02
Drugs
anti-NY-ESO-1 TCR-TUI-201
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCT2090220346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2090220346.